macular edema therapy using dexamethasone nanoparticle suspension PURPOSE To determine the effectiveness and safety of a new topical nanoparticle dexamethasone ophthalmic suspension OCS-01 (Oculis SA, Lausanne, Switzerland) in the treatment of diabetic macular edema (DME). STUDY BACKGROUND Diabetic macular edema (DME) is the main cause of visual impairment in patients with diabetic retinopathy (DR).
Ophthalmology
Cholesterol Screening To Aid In Glaucoma Detection
Cholesterol Screening To Aid In Glaucoma Detection Overview Although intraocular pressure is the primary risk factor for glaucoma, additional risk factors should also be considered. This systematic review and meta-analysis summarize the evidence of the association between cholesterol parameters (total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels) and glaucoma and
Cochlear Implants and Vestibular Screening
Cochlear Implants and Vestibular Screening The Study Vestibular dysfunction is one of the many risks of placing a cochlear implant (CI). However, the use of the physical exam to screen CI candidates for vestibular dysfunction is not studied enough. The study’s goal is to explore the preoperative role of the clinical head
How to Control Eye Pressure in Glaucoma
Patient Education This article is tailored for patients. Refer your patients to this article for them to learn more about their condition. How to Control Eye Pressure in Glaucoma The irreversible damage of glaucoma is one of the leading causes of blindness among people ages 60 years and above(1). This condition is
Extrapontine Myelinolysis and Pituitary Tumor Apoplexy in Pregnancy
Extrapontine Myelinolysis and Pituitary Tumor Apoplexy in Pregnancy Background Pituitary tumor apoplexy (PTA) is an uncommon but potentially fatal clinical emergency resulting from abrupt ischemic infarction or hemorrhage of the pituitary tumor. A variety of precipitating factors has been linked to PTA, including pregnancy. However, gestational pituitary apoplexy is limited to isolated
Optic 3D Modeling in Ophthalmic Treatment
Optic 3D Modeling in Ophthalmic Treatment Visual impairment is a global health concern. Visually impaired patients are at high risk for accidents, depression, and social withdrawal. Eye disorders like age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and retinitis pigmentosa (RP) cause irreparable vision loss and affect the quality of life of
iStent Combination Therapy for Glaucoma and Cataracts
iStent Combination Therapy for Glaucoma and Cataracts Considering that glaucoma is the most common cause of irreversible vision loss and the third most common cause of vision loss worldwide, with cataracts and refractive error being the most prevalent causes, iStent combination therapy to treat glaucoma and cataracts has high therapeutic value.
Second Primary Malignancies of Eye and Ocular Adnexa
Thermography in clinical ophthalmic oncology
THERMOGRAPHY AS A SCREENING TOOL IN CLINICAL OPHTHALMIC ONCOLOGY STUDY BACKGROUND Although intraocular tumors are rare, with an incidence of 5 per million adults, the diagnosis has been biased towards the physical examination, Color Doppler Imaging (CDI), Optical Coherence Tomography (OCT), Indocyanine Green Angiography (ICGA), or Fluorescein Angiography (FA). Literature reviews suggest
Combination IOP Reduction Therapy in Open-Angle Glaucoma
Combination IOP Reduction Therapy in Open-Angle Glaucoma GLAUCOMA BACKGROUND Globally, glaucoma is a leading cause of permanent blindness. As of 2020, about 80 million people worldwide, and 3 million Americans, are affected by glaucoma. The most common form of glaucoma is open-angle glaucoma. Unfortunately, the primary risk factor for open-angle glaucoma is
